Andreas Barratt-Due, Kristin Pettersen, Tuva Børresdatter-Dahl, Jan Cato Holter, Renathe H. Grønli, Anne Ma Dyrhol-Riise, Tøri Vigeland Lerum, Aleksander Rygh Holten, Kristian Tonby, Marius Trøseid, Ole H. Skjønsberg, Beathe Kiland Granerud, Lars Heggelund, Anders Benjamin Kildal, Camilla Schjalm, Trond Mogens Aaløkken, Pål Aukrust, Thor Ueland, Tom Eirik Mollnes, Bente Halvorsen, NOR-Solidarity study groupThe Norwegian SARS-CoV-2 study group
{"title":"SARS-CoV-2 感染者住院期间补体激活升级与 60 天内死亡风险升高有关。","authors":"Andreas Barratt-Due, Kristin Pettersen, Tuva Børresdatter-Dahl, Jan Cato Holter, Renathe H. Grønli, Anne Ma Dyrhol-Riise, Tøri Vigeland Lerum, Aleksander Rygh Holten, Kristian Tonby, Marius Trøseid, Ole H. Skjønsberg, Beathe Kiland Granerud, Lars Heggelund, Anders Benjamin Kildal, Camilla Schjalm, Trond Mogens Aaløkken, Pål Aukrust, Thor Ueland, Tom Eirik Mollnes, Bente Halvorsen, NOR-Solidarity study groupThe Norwegian SARS-CoV-2 study group","doi":"10.1111/joim.13783","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The complement system, an upstream recognition system of innate immunity, is activated upon SARS-CoV-2 infection. To gain a deeper understanding of the extent and duration of this activation, we investigated complement activation profiles during the acute phase of COVID-19, its persistence post-recovery and dynamic changes in relation to disease severity.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Serial blood samples were obtained from two cohorts of hospitalized COVID-19 patients (<i>n</i> = 457). Systemic complement activation products reflecting classical/lectin (C4d), alternative (C3bBbP), common (C3bc) and terminal pathway (TCC and C5a) were measured during hospitalization (admission, days 3–5 and days 7–10), at 3 months and after 1 year. Levels of activation and temporal profiles during hospitalization were related to disease severity defined as respiratory failure (PO<sub>2</sub>/FiO<sub>2</sub> ratio <26.6 kPa) and/or admission to intensive care unit, 60-day total mortality and pulmonary pathology after 3 months.</p>\n </section>\n \n <section>\n \n <h3> Findings</h3>\n \n <p>During hospitalization, TCC, C4d, C3bc, C3bBbP and C5a were significantly elevated compared to healthy controls. Severely ill patients had significantly higher levels of TCC and C4d (<i>p </i>< 0.001), compared to patients with moderate COVID-19. Escalated levels of TCC and C4d during hospitalization were associated with a higher risk of 60-day mortality (<i>p </i>< 0.001), and C4d levels were additionally associated with chest CT changes at 3 months (<i>p </i>< 0.001). At 3 months and 1 year, we observed consistently elevated levels of most complement activation products compared to controls.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Hospitalized COVID-19 patients display prominent and long-lasting systemic complement activation. Optimal targeting of the system may be achieved through enhanced risk stratification and closer monitoring of in-hospital changes of complement activation products.</p>\n </section>\n </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":9.0000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13783","citationCount":"0","resultStr":"{\"title\":\"Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients\",\"authors\":\"Andreas Barratt-Due, Kristin Pettersen, Tuva Børresdatter-Dahl, Jan Cato Holter, Renathe H. Grønli, Anne Ma Dyrhol-Riise, Tøri Vigeland Lerum, Aleksander Rygh Holten, Kristian Tonby, Marius Trøseid, Ole H. Skjønsberg, Beathe Kiland Granerud, Lars Heggelund, Anders Benjamin Kildal, Camilla Schjalm, Trond Mogens Aaløkken, Pål Aukrust, Thor Ueland, Tom Eirik Mollnes, Bente Halvorsen, NOR-Solidarity study groupThe Norwegian SARS-CoV-2 study group\",\"doi\":\"10.1111/joim.13783\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>The complement system, an upstream recognition system of innate immunity, is activated upon SARS-CoV-2 infection. To gain a deeper understanding of the extent and duration of this activation, we investigated complement activation profiles during the acute phase of COVID-19, its persistence post-recovery and dynamic changes in relation to disease severity.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Serial blood samples were obtained from two cohorts of hospitalized COVID-19 patients (<i>n</i> = 457). Systemic complement activation products reflecting classical/lectin (C4d), alternative (C3bBbP), common (C3bc) and terminal pathway (TCC and C5a) were measured during hospitalization (admission, days 3–5 and days 7–10), at 3 months and after 1 year. Levels of activation and temporal profiles during hospitalization were related to disease severity defined as respiratory failure (PO<sub>2</sub>/FiO<sub>2</sub> ratio <26.6 kPa) and/or admission to intensive care unit, 60-day total mortality and pulmonary pathology after 3 months.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Findings</h3>\\n \\n <p>During hospitalization, TCC, C4d, C3bc, C3bBbP and C5a were significantly elevated compared to healthy controls. Severely ill patients had significantly higher levels of TCC and C4d (<i>p </i>< 0.001), compared to patients with moderate COVID-19. Escalated levels of TCC and C4d during hospitalization were associated with a higher risk of 60-day mortality (<i>p </i>< 0.001), and C4d levels were additionally associated with chest CT changes at 3 months (<i>p </i>< 0.001). At 3 months and 1 year, we observed consistently elevated levels of most complement activation products compared to controls.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Hospitalized COVID-19 patients display prominent and long-lasting systemic complement activation. Optimal targeting of the system may be achieved through enhanced risk stratification and closer monitoring of in-hospital changes of complement activation products.</p>\\n </section>\\n </div>\",\"PeriodicalId\":196,\"journal\":{\"name\":\"Journal of Internal Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13783\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/joim.13783\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/joim.13783","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
Background
The complement system, an upstream recognition system of innate immunity, is activated upon SARS-CoV-2 infection. To gain a deeper understanding of the extent and duration of this activation, we investigated complement activation profiles during the acute phase of COVID-19, its persistence post-recovery and dynamic changes in relation to disease severity.
Methods
Serial blood samples were obtained from two cohorts of hospitalized COVID-19 patients (n = 457). Systemic complement activation products reflecting classical/lectin (C4d), alternative (C3bBbP), common (C3bc) and terminal pathway (TCC and C5a) were measured during hospitalization (admission, days 3–5 and days 7–10), at 3 months and after 1 year. Levels of activation and temporal profiles during hospitalization were related to disease severity defined as respiratory failure (PO2/FiO2 ratio <26.6 kPa) and/or admission to intensive care unit, 60-day total mortality and pulmonary pathology after 3 months.
Findings
During hospitalization, TCC, C4d, C3bc, C3bBbP and C5a were significantly elevated compared to healthy controls. Severely ill patients had significantly higher levels of TCC and C4d (p < 0.001), compared to patients with moderate COVID-19. Escalated levels of TCC and C4d during hospitalization were associated with a higher risk of 60-day mortality (p < 0.001), and C4d levels were additionally associated with chest CT changes at 3 months (p < 0.001). At 3 months and 1 year, we observed consistently elevated levels of most complement activation products compared to controls.
Conclusion
Hospitalized COVID-19 patients display prominent and long-lasting systemic complement activation. Optimal targeting of the system may be achieved through enhanced risk stratification and closer monitoring of in-hospital changes of complement activation products.
期刊介绍：
JIM – The Journal of Internal Medicine, in continuous publication since 1863, is an international, peer-reviewed scientific journal. It publishes original work in clinical science, spanning from bench to bedside, encompassing a wide range of internal medicine and its subspecialties. JIM showcases original articles, reviews, brief reports, and research letters in the field of internal medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
